PEB-Pacific Edge

[Habitz]

Its good to see some well placed attention and interest on the stock. This stock was the darling of 2020, if they pull off the AUA it might happen again.

[winner (n)]

Its good to see some well placed attention and interest on the stock. This stock was the darling of 2020, if they pull off the AUA it might happen again.

Lost that darling status when Darling left

[Habitz]

Lost that darling status when Darling left

Thats true. We need someone with a new surname for the current challenges, to create the right impression, to take us to new heights of success, a name like "winner" will do.

[LoungeLizard]

Lost that darling status when Darling left

That's Captain Darling....

[LoungeLizard]

Excellent synopsis presented by Pierre on the other site.

Totally agree that we are perhaps at the beginning of a chain of events starting with PEB getting included in the new AUA guidelines and ending with Novitas re-instating permanent coverage. The time frame for that is anyone's guess, but mine is 6 months or less.

Getting included in the new AUA guidelines is key, not just to put pressure on Novitas, but for the fact that the they govern the practices of all urologists. I think there's only something like 12% of urologists in the US that currently have used CXBladder, but if the new guidelines explicitly endorse and recommend its use as  a safe, accurate, screening tool, then PEB's use by practitioners will go through the roof, as will throughput and revenue.

I hope that's how things turn out, not just because I hold far more stock than is sensible, but because I've always believed in the positive health benefits that PEB's products provide. That's the true double-bagger: making money whilst doing good  
 
 

[Pierre]

I'm currently in Japan where I tried to log on to the PEB ASM on my phone. Unfortunately the virtual meeting technology only works on a PC so I can't access the meeting.

I will appreciate an update of any pertinent information from anyone who is able to attend either in person or online.

[LoungeLizard]

I'm currently in Japan where I tried to log on to the PEB ASM on my phone. Unfortunately the virtual meeting technology only works on a PC so I can't access the meeting.

I will appreciate an update of any pertinent information from anyone who is able to attend either in person or online.

You're more on the ball than I Pierre. Forgot to log-in entirely. The presentation and Chairmans address is now on the PEB website.
The presentation sounds fairly positive as you would expect, but wisely they are not trying to predict anything around the upcoming new AUA guidelines and the Novitas decision other than noting "the direction of travel" from the Strata study and strong industry support.
Not sure if there was anything revelatory in the Q/A session? 

[Greekwatchdog]

You're more on the ball than I Pierre. Forgot to log-in entirely. The presentation and Chairmans address is now on the PEB website.
The presentation sounds fairly positive as you would expect, but wisely they are not trying to predict anything around the upcoming new AUA guidelines and the Novitas decision other than noting "the direction of travel" from the Strata study and strong industry support.
Not sure if there was anything revelatory in the Q/A session? 

I haven't heard anything other than what I read which is positive with work to do to get over the line. Not surprised at share price falling. Market got a little carried away for mine

[Left Field]

I will appreciate an update of any pertinent information from anyone who is able to attend either in person or online.

Re PEB ASM 24/9/24

I watched/listened to today's meeting online because PEB is one of very few underperforming companies in my otherwise beautiful and profitable portfolio!

It was a very long meeting.... over 2 hours

Some notes FWIW

- No assurances or timeline re Novitas were given, (hence the drop in SP today?) IMHO these expectations were unrealisitc at this time. Novitas runs to its own schedule.... not to PEB's.
- Any selection of a new Chairperson for PEB is on hold until a Novitas decision is made.Current Chair has agreed to remain in place to allow orderly transition.
- In all respects the meeting was extremely positive.
- The buffer of $53 mill on hand is being managed prudently until such time as further progress can be made in terms of Novitas and revised AUA guidelines
- After today's ASM the Board and key managers are having a 2 day retreat for future plans which will cover a.) recovery under a negative Novitas decision. b.) Accelerated growth under a positive decision.
- PEB very positive that the seperate (and timely)  AUA guideline review will conclude with positive benefits to PEB (possible timeline not given..... I estimate as likely in FY25.)
- PEB progressing strongly with other initiatives. eg an online customer portal has just been launched (after trials with Kaiser) and will increase efficiencies and accurate data collection.
- New product Detect Plus (Detect+) has huge potential as is much superior to current PEB products and is ready for launch as soon as agreement on pricing is reached with US authorities.
- CEO Peter Meintjes impresses as very skilled and knowledgeable in these difficult times.
- The CEO noted that PEB has now weathered the storm for 2 years and PEB  are now seeing more options for positive progress than they are for negative.
- In the Q & A session the Q of possible legal action against Novitas was raised. PEB is prepared for this, but does not see it as a priority. Any legal action will depend on the circumstances and will not be 'at huge cost' as PEB would prefer to spend its $'s on research to validate its clinical utility.
USA remains the priority market
- The newly formed Medical Affairs team has been a great success. (Doctors talking to Doctors are much more effective than sales people talking to Doctors.)

The meeting included slides which can be seen here; https://api.nzx.com/public/announcement/438709/attachment/427932/438709-427932.pdf

ps.... I note I have now topped 1,000 posts and that is likely enough for me. I'm not planning on posting any more.
Best wishes all..... I'll be watching from afar.

[Habitz]

"a.) recovery under a negative Novitas decision. b.) Accelerated growth under a positive decision."

A TWO horse race where option a.) is partial loss and option b.) is multibag 5 or 10:1 ??

[Magic78]

Great summary Left Field.

Also worth noting CEO mentioned companies aren't usually asked by the AUA to be involved in guideline discussions, so interesting PEB consultant was asked to contribute.

[Shareguy]

Re PEB ASM 24/9/24

I watched/listened to today's meeting online because PEB is one of very few underperforming companies in my otherwise beautiful and profitable portfolio!

It was a very long meeting.... over 2 hours

Some notes FWIW

- No assurances or timeline re Novitas were given, (hence the drop in SP today?) IMHO these expectations were unrealisitc at this time. Novitas runs to its own schedule.... not to PEB's.
- Any selection of a new Chairperson for PEB is on hold until a Novitas decision is made.Current Chair has agreed to remain in place to allow orderly transition.
- In all respects the meeting was extremely positive.
- The buffer of $53 mill on hand is being managed prudently until such time as further progress can be made in terms of Novitas and revised AUA guidelines
- After today's ASM the Board and key managers are having a 2 day retreat for future plans which will cover a.) recovery under a negative Novitas decision. b.) Accelerated growth under a positive decision.
- PEB very positive that the seperate (and timely)  AUA guideline review will conclude with positive benefits to PEB (possible timeline not given..... I estimate as likely in FY25.)
- PEB progressing strongly with other initiatives. eg an online customer portal has just been launched (after trials with Kaiser) and will increase efficiencies and accurate data collection.
- New product Detect Plus (Detect+) has huge potential as is much superior to current PEB products and is ready for launch as soon as agreement on pricing is reached with US authorities.
- CEO Peter Meintjes impresses as very skilled and knowledgeable in these difficult times.
- The CEO noted that PEB has now weathered the storm for 2 years and PEB  are now seeing more options for positive progress than they are for negative.
- In the Q & A session the Q of possible legal action against Novitas was raised. PEB is prepared for this, but does not see it as a priority. Any legal action will depend on the circumstances and will not be 'at huge cost' as PEB would prefer to spend its $'s on research to validate its clinical utility.
USA remains the priority market
- The newly formed Medical Affairs team has been a great success. (Doctors talking to Doctors are much more effective than sales people talking to Doctors.)

The meeting included slides which can be seen here; https://api.nzx.com/public/announcement/438709/attachment/427932/438709-427932.pdf

ps.... I note I have now topped 1,000 posts and that is likely enough for me. I'm not planning on posting any more.
Best wishes all..... I'll be watching from afar.

An excellent summery of the meeting Left field.

[LoungeLizard]

Re PEB ASM 24/9/24

ps.... I note I have now topped 1,000 posts and that is likely enough for me. I'm not planning on posting any more.
Best wishes all..... I'll be watching from afar.

A thousand posts? That's a long tour of duty!
I've appreciated your comments and insights  -take a well earned furlough!

[Pierre]

Thanks so much Left Field - I really appreciate your comprehensive summary.

More watching and waiting required now, but it does seem there are grounds for a potentially positive outcome. How positive and for how long do we have to wait, are the unanswerable questions.

[Ferg]

I understand biotech patents are important for the US market (which is the PEB focus, for now) but the patents on the PEB website do not mesh with what can be seen online at the US patent office.  It appears they have a handful of US patents and applications in progress.

Found here: https://ppubs.uspto.gov/pubwebapp/static/pages/ppubsbasic.html

Patent numbers, expiry dates & {brief description}:

• 10689707 expired {gastric cancer treatment} - see 10024859 below
• 11180815 exp 2027 {colorectal cancer treatment}
• 10689711 exp 2027 {urothelial carcinoma treatment} - see 10131955 below
• 9809860 exp 2028 {test kits & genetic markers}
• 9534258 exp 2028 {melanoma patent mentioned on their website}
• 10024859 exp 2030 {detecting gastric cancer markers}
• 11208698 exp 2032 {bladder cancer markers detection}
• 10131955 exp 2034? {detecting biomarkers of urothelial carcinoma}

Plus about 14 other applications from what I can see.

They don't seem to mention all the US patents on this page:
https://www.pacificedgedx.com/company/intellectual-property/

Probably worth asking about given biotech patents have the potential for huge values, and huge lawsuits.